Combination of anti-muscarinic agents and non-glucocorticoid steroids

Details for Australian Patent Application No. 2003276837 (hide)

Owner Epigenesis Pharmaceuticals, LLC.

Inventors Robinson, Cynthia B.; Nyce, Jonathan W.

Agent Fisher Adams Kelly

Pub. Number AU-B-2003276837

PCT Number PCT/US03/18967

PCT Pub. Number WO2004/014293

Priority 60/388,170 12.06.02 US

Filing date 12 June 2003

Wipo publication date 25 February 2004

Acceptance publication date 20 July 2006

International Classifications

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

19 February 2004 Complete Application Filed

  Priority application(s): 60/388,170 12.06.02 US

8 April 2004 Application Open to Public Inspection

  Published as AU-B-2003276837

16 June 2005 Assignment before Grant

  Epigenesis Pharmaceuticals, Inc. The application has been assigned to Epigenesis Pharmaceuticals, LLC.

23 March 2006 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 18 Nov 2004 2004

20 July 2006 Application Accepted

  Published as AU-B-2003276837

30 November 2006 Standard Patent Sealed

19 January 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003276838-HYDROXYL FREE RADICAL-INDUCED DECONTAMINATION OF AIRBORNE SPORES, VIRUSES AND BACTERIA IN A DYNAMIC SYSTEM

2003276836-Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof